(63 days)
Not Found
No
The description focuses on material changes to a wound dressing and does not mention any AI/ML capabilities or related performance metrics.
Yes
The device is a wound dressing indicated for the management of deep secondary healing wounds, which are therapeutic purposes.
No
Explanation: The device, Cutinova cavity, is described as a polyurethane dressing indicated for the management of deep secondary healing wounds. Its intended use is for treatment and wound care, not for diagnosing a condition or disease.
No
The device description explicitly states it is a "polyurethane dressing," which is a physical, hardware component, not software.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states the device is for the "management of deep secondary healing wounds." This describes a therapeutic or wound care application, not a diagnostic test performed on samples taken from the body.
- Device Description: The description details a "polyurethane dressing" used for wound management. This is a physical dressing applied to a wound, not a reagent or instrument used to analyze biological samples.
- Lack of IVD Characteristics: The text does not mention any of the typical characteristics of an IVD, such as:
- Analyzing biological samples (blood, urine, tissue, etc.)
- Detecting or measuring specific substances (analytes)
- Providing information for diagnosis, monitoring, or screening
The device is a wound dressing, which falls under the category of medical devices used for treatment and management, not in vitro diagnosis.
N/A
Intended Use / Indications for Use
Cutinova cavity is indicated for the management of deep secondary healing wounds such as: Cavity wounds Stage III and IV pressure ulcers Deep leg ulcers Excisions Post-op wound dehiscence
Product codes
FRO
Device Description
Cutinova cavity is a polyurethane dressing that is indicated for the management of deep secondary healing wounds. The current modification involves a change in the material used to make the urethane from an aromatic disocyanate to an aliphatic diisocyanate and does not affect the indications for use.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Biological tests were done in accordance with ISO 10993 and showed no negative effects for the modified Cutinova cavity. Performance characteristics were also comparable to the currently marketed product. In addition, a very small amount of & Tocopherol was added to improve the thermal stability of the product.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
N/A
0
04:47PM JOBST CHAR FEB 12 '99
3/1/99
1984597
Summary of Safety and Effectiveness for Cutinova@ cavity - K984597
This 510(k) is being submitted for a modification to Cutinova cavity that was originally cleared for sale in the U.S. in 1995 (K952526)
Cutinova cavity is a polyurethane dressing that is indicated for the management of deep secondary healing wounds. The current modification involves a change in the material used to make the urethane from an aromatic disocyanate to an aliphatic diisocyanate and does not affect the indications for use.
Biological tests were done in accordance with ISO 10993 and showed no negative effects for the modified Cutinova cavity. Performance characteristics were also comparable to the currently marketed product. In addition, a very small amount of & Tocopherol was added to improve the thermal stability of the product.
Based on safety information in international data bases, biological testing and performance characteristics, it can be concluded that the modified Cutinova cavity is substantially equivalent to the current legally marketed Cutinova cavity.
Dated: February 9, 1999
Prepared by: Angelo Pereira Manager, Regulatory Affairs Beiersdorf-Jobst Inc. 5825 Carnegie Boulevard Charlotte, N.C. 28209
1
Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized design of three human profiles facing right, arranged in a stacked formation. The profiles are rendered in a dark color, creating a sense of depth and unity. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" is arranged in a circular fashion around the profile graphic.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
MAR 1 9 2007
Mr. Angelo Pereira Beiersdorf-Jobst, Inc. 5825 Carnegie Boulevard Charlotte, North Carolina 28209-4633
Re: K984597 Trade Name: Cutinova Cavity Wound Dressing Regulatory Class: Unclassified Product Code: FRO Dated: December 23, 1998 Received: December 28, 1998
Dear Mr. Pereira:
This letter corrects our substantially equivalent letter of March 1, 1999.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act including requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration and the following limitations:
-
This device may not be labeled for use on third degree burns.
-
This device may not be labeled as having any accelerating effect on the rate of wound healing or epithelization.
-
This device may not be labeled as a long-term, permanent, or no-change dressing, or as an artificial (synthetic) skin.
2
Page 2 - Mr. Angelo Pereira
- This device may not be labeled as a treatment or a cure for any type of wound.
The labeling claims listed above would be considered a major modification in the intended use of the device and would require a premarket notification submission (21 CFR 807.81).
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to continue marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
3
Page 3 - Mr. Angelo Pereira
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely vours,
Mark M. Mellema
Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
4
Image /page/4/Picture/1 description: The image contains a sequence of handwritten digits and a letter. The sequence starts with the letter 'K', followed by the numbers '9', '8', '4', '5', '9', and '7'. The numbers are written in a connected manner, resembling cursive handwriting. The digits are all similar in size and are written in black ink.
Page 1 of 1
. ແ
510(k) Number (if known): _
Device name: Cutinova cavity
Indications For Use:
Cutinova cavity is indicated for the management of deep secondary healing wounds such as: Cavity wounds Stage III and IV pressure ulcers Deep leg ulcers Excisions
Post-op wound dehiscence
(PLEASE DO NOT WRITE BELOW THIS LINE. CONTINUE ON ANOTHER PAGE IF NEEDED)
| Concurrence of CDRH, Office of Device Evaluation (ODE) | |
|---|---|
| Prescription Use | |
| (Per 21 CFR 801.109) | X |
| OR Over The Counter Use | |
| (Division Sign-Off) | |
| Division of General Restorative Devices | |
| 510(k) Number | K984597 |
-
- 199
5
Page 1 of 1
510(k) Number
K984597
Device name: Cutinova cavity
Over-the-Counter Indications For Use:
Cutinova cavity may be used under the direction of a health care professional for the management of deep secondary healing wounds such as:
Cavity wounds Stage III and IV pressure ulcers Deep leg ulcers Excisions Post-op wound dehiscence
(PLEASE DO NOT WRITE BELOW THIS LINE. CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use, (Per 21 CFR 801.109)
OR Over The Counter Use X
(Division Sign Off) Division of General Restorative Devices 510(k) Number